Intracranial angioplasty and stent placement for cerebral atherosclerosis.
Intracranial atherosclerotic stenoses have been estimated to account for 8%-10% of all ischemic strokes. A substantial number of patients fail the best medical treatment, which includes control of vascular risk factors and administration of antithrombotics (platelet-active drugs or warfarin), statins, and angiotensin-converting enzyme inhibitors. In these patients, angioplasty with stent placement is one reasonable treatment option for preventing massive ischemic stroke. Herein, we discuss basic pathophysiologic concepts and their effect on endovascular revascularization procedures.
Schumacher
H Christian
HC
Doris and Stanley Tananbaum Stroke Center, Neurological Institute, New York-Presbyterian Hospital, College of Physicians & Surgeons, Columbia University, 710 West 168th Street, New York, NY 10032, USA.
Khaw
Alexander V
AV
Meyers
Philip M
PM
Gupta
Rishi
R
Higashida
Randall T
RT
D017130:Angioplasty; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D019917:Blood Vessel Prosthesis Implantation; D002545:Brain Ischemia / Q000453:epidemiology / Q000517:prevention & control; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D002537:Intracranial Arteriosclerosis / Q000453:epidemiology / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D012307:Risk Factors; D015607:Stents; D020521:Stroke / Q000453:epidemiology / Q000517:prevention & control; D014481:United States / Q000453:epidemiology
D000806:Angiotensin-Converting Enzyme Inhibitors; D005343:Fibrinolytic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors